Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NuSepin intravenous infusion in COVID-19 pneumonia (Phase 2b/3 adaptive RCT)
2022-001152-42Phase 2Completed
- Sponsor
- Shaperon
- Start
- May 2022
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing NuSepin intravenous infusion with Placebo intravenous infusion (2 arms). Primary endpoint: Time to 2-point improvement on WHO 8-point ordinal scale (Phase 2b primary). Started May 2022; status: completed.
02
Drugs
hy209gel
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-001152-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001152-42.